# EDGAR Filing Document

**Accession Number:** 0001478242
**File Stem:** 0001193125-26-212463
**Filing Date:** 2026-5
**Character Count:** 8329
**Document Hash:** e9edca1b630d49b33977939dbddabb81
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-212463.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001193125-26-212463

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260507

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IQVIA HOLDINGS INC.
- **CENTRAL INDEX KEY:** 0001478242
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 271341991
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35907
- **FILM NUMBER:** 26954962

**BUSINESS ADDRESS:**
- **STREET 1:** 2400 ELLIS ROAD
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** 919-998-2000

**MAIL ADDRESS:**
- **STREET 1:** 2400 ELLIS ROAD
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Quintiles IMS Holdings, Inc.
- **DATE OF NAME CHANGE:** 20161003

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Quintiles Transnational Holdings Inc.
- **DATE OF NAME CHANGE:** 20091208

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): May 7, 2026

## IQVIA HOLDINGS INC.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-35907** | **27-1341991** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |

---

#### 2400 Ellis Road

#### Durham, North Carolina 27703

#### (Address of principal executive offices)

#### Registrant's telephone number, including area code: (919) 998-2000

#### Not Applicable

#### (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading<br>Symbol** | **Name of Each Exchange<br>on which Registered** |
| Common Stock, par value $0.01 per share | "IQV" | New York Stock Exchange LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01.** | **Other Events.**  |

---

On May 7, 2026, IQVIA Holdings Inc. (the "Company") announced that the Company's board of directors authorized the repurchase of an additional $2,000 million of the Company's common stock under the Company's existing equity repurchase program (the "Repurchase Program"), bringing the total remaining authorization to $3,217 million. A copy of the press release is attached and incorporated herein by reference as Exhibit 99.1.

The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time. The timing and amount of repurchases are determined by the Company's management based on a variety of factors such as the market price of the Company's common stock, the Company's corporate requirements, and overall market conditions. Purchases of the Company's common stock may be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. The Repurchase Program does not have an expiration date. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. The Company may discontinue repurchases without notice at any time.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit Description** |
| 99.1 | [Press Release, dated May 7, 2026.](d114471dex991.htm) |
|  104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 7, 2026

---

| | |
|:---|:---|
| **IQVIA HOLDINGS INC.** | **IQVIA HOLDINGS INC.** |
| By: | /s/ Michael J. Fedock |
|  | Michael J. Fedock |
|  | Executive Vice President and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![LOGO](g114471g78y80.jpg)

**News Release** 

Contacts:

Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)

+1.973.541.3558

Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)

+1.919.923.6785

**IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization** 

**RESEARCH TRIANGLE PARK, N.C.** – May 7, 2026 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that its board of directors authorized the repurchase of an additional $2 billion of IQVIA's common stock under IQVIA's existing equity repurchase program (the "Repurchase Program"), bringing the total remaining authorization to $3.2 billion.

The Repurchase Program does not obligate IQVIA to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time. The timing and amount of repurchases are determined by IQVIA's management based on a variety of factors such as the market price of IQVIA's common stock, IQVIA's corporate requirements, and overall market conditions. Purchases of IQVIA's common stock may be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. The Repurchase Program does not have an expiration date. In addition, from time to time, IQVIA has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. IQVIA may discontinue repurchases without notice at any time.

**About IQVIA** 

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances in an effort to advance their path toward cures. To learn more, visit <u>www.iqvia.com</u>.

IQVIAFIN

# # #